LATEST
Tue, Nov 17, 2026
Loading weather...
Markets

Roche Wins Dual FDA Approvals for Breast Cancer and Chronic Kidney Disease Therapies

On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments ac...

On Monday, Roche Holdings AG (OTC:RHHBY) announced that the U.S. Food and Drug Administration approved two treatments across its breast cancer and immunology portfolios, clearing Wilserdly for advanced breast cancer and Gazyva/Gazyvaro for chronic kidney disease. FDA Approves Oral Breast Cancer Combination Wilserdly The FDA approved Wilserdly (giredestrant) plus everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated locally advanced or...

SOURCE: Benzinga
ORIGINAL REPORT: Click here
DHALLO EDITORIAL STATUS: Aggregated & reviewed
Have feedback on this article?Report error or suggestion

Read More from Markets

MongoDB Buys Firebolt to Help AI Agents Make Split-Second Decisions

MongoDB Inc. (NASDAQ:MDB) announced Tuesday that it acquired analytics company F...

Read Article »

Siyata Mobile Inc. Reports Third Quarter 2026 Financial Results Under New Name Core AI Holdings, Inc.

Core AI Holdings, Inc. (formerly Siyata Mobile Inc.) reported its unaudited fina...

Read Article »

NSA Hit by Major Network Outage as Tech Glitches Pile Up

The highly classified network the National Security Agency (NSA) uses for intern...

Read Article »
Return to Front Page

5 minutes. The news that matters.

Get the most important stories of the day, without having to browse hundreds of articles.